Get the latest news, insights, and market updates on EWTX (Edgewise Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Edgewise Therapeutics (EWTX): Evaluating Valuation as New Long-Term Clinical Data Sparks Investor Interest
Edgewise Therapeutics (EWTX) is drawing attention as it prepares to share new long-term clinical data for its lead drug candidate, sevasemten, at the upcoming World Muscle Society Congress. See our latest analysis for Edgewise Therapeutics. Building anticipation around the upcoming data presentation, Edgewise Therapeutics has experienced some volatility, with a 7.45% gain in the last 90 days but a steeper year-to-date share price return of -43.99%. Over the past three years, however,... Oct 8, 2025 - $EWTX
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle Society (WMS). Importantly, the presentations will include a compilation of long-term data of sevasemten in Becker demonstrating sustained disease stabilization compared to natural history. Sevasemten is an orally administered small molecule designed to prevent contraction-induced muscle damage in muscular Oct 2, 2025 - $EWTX
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment
Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise Therapeutics announced positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. For Becker muscular dystrophy, the company reported positive data from MESA, which is an open-label extension trial that provides continued […] Jul 4, 2025 - $EWTX
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated filing for sevasemten in Becker muscular dystrophy, but the company will explore additional avenues to speed the process, and will seek full approval with GRAND CANYON, the analyst tells investors in a research note. Wedbush still sees several unanswered questio Jun 28, 2025 - $EWTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple